Addyi was first authorised with the FDA in August 2015 to treat hypoactive sexual motivation problem (HSDD) in premenopausal women. Which is just another way of claiming it boosts sex travel (also referred to as libido) in Women of all ages who may have not reached menopause. It had been https://walterp528yzy6.bloguerosa.com/profile